
    
      The primary objective of the study was to assess the safety and tolerability of multiple
      subcutaneous injections of BAY1093884 (anti-TFPI monoclonal antibody, immunoglobulin G2,
      IgG2) in patients with hemophilia A or B with or without inhibitors.
    
  